subject area of
- CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention Academic Article
- Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial Academic Article
- Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem Academic Article
- Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting Academic Article
- Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study Academic Article
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment Academic Article
- Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis Academic Article
- Impact of Insulin Receptor Substrate‐1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention Academic Article
- Review of aspirin and clopidogrel resistance in peripheral arterial disease Academic Article
- Role of phenotypic and genetic testing in managing clopidogrel therapy Academic Article
- The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis Academic Article
- The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study Academic Article